Journal Summary - Discover more summaries and articles from M3 India

Journal Summaries

Oncology

Lung/Thoracic Oncology

Clinical efficacy analysis of preoperative neoadjuvant chemotherapy in patients with pulmonary adenocarcinoma during stage IIIA

Journal of Global Oncology | Oct 20, 2019 Lung/Thoracic Oncology

Cancer statistics for adults aged 85 years and older, 2019

CA: A Cancer Journal for Clinicians | Oct 18, 2019 Lung/Thoracic Oncology

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): A randomised, controlled, phase 3 study

The Lancet Oncology | Oct 18, 2019 Lung/Thoracic Oncology

Family history of cancer and subsequent risk of cancer: A large-scale population-based prospective study in Japan

International Journal of Cancer | Oct 18, 2019 Lung/Thoracic Oncology

Patient-reported outcomes from the randomized phase 3 ALEX study of alectinib vs crizotinib in patients with ALK-positive non-small-cell lung cancer

Lung Cancer | Oct 18, 2019 Lung/Thoracic Oncology

Mendelian randomization study of telomere length and lung cancer risk in East Asian population

Cancer Medicine | Oct 18, 2019 Lung/Thoracic Oncology

Durvalumab plus platinum–etoposide vs platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial

The Lancet | Oct 17, 2019 Lung/Thoracic Oncology

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

The Lancet Oncology | Oct 15, 2019 Lung/Thoracic Oncology

The prediction of epidermal growth factor receptor mutation and prognosis of EGFR tyrosine kinase inhibitor by serum ferritin in advanced NSCLC

Cancer Management and Research | Oct 15, 2019 Lung/Thoracic Oncology

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology | Oct 14, 2019 Lung/Thoracic Oncology

« Prev 1 … 67 68 69 70 71 … 149 Next »

Clinical efficacy analysis of preoperative neoadjuvant chemotherapy in patients with pulmonary adenocarcinoma during stage IIIA

Cancer statistics for adults aged 85 years and older, 2019

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): A randomised, controlled, phase 3 study

Family history of cancer and subsequent risk of cancer: A large-scale population-based prospective study in Japan

Patient-reported outcomes from the randomized phase 3 ALEX study of alectinib vs crizotinib in patients with ALK-positive non-small-cell lung cancer

Mendelian randomization study of telomere length and lung cancer risk in East Asian population

Durvalumab plus platinum–etoposide vs platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

The prediction of epidermal growth factor receptor mutation and prognosis of EGFR tyrosine kinase inhibitor by serum ferritin in advanced NSCLC

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial

BRI or BMI: What is More Efficient?

Enhancing Conventional Diabetes Management with Lifestyle and Nutritional Interventions

Gut Health Disorders and its Management

Addressing Sleep Disorders with Integrative Solutions: From Pharmaceuticals to Natural Remedies

MIP: Traumatic Brain Injury : Dr Nikhilesh Jain

Clinical efficacy analysis of preoperative neoadjuvant chemotherapy in patients with pulmonary adenocarcinoma during stage IIIA

Cancer statistics for adults aged 85 years and older, 2019

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): A randomised, controlled, phase 3 study

Family history of cancer and subsequent risk of cancer: A large-scale population-based prospective study in Japan

Patient-reported outcomes from the randomized phase 3 ALEX study of alectinib vs crizotinib in patients with ALK-positive non-small-cell lung cancer

Mendelian randomization study of telomere length and lung cancer risk in East Asian population

Durvalumab plus platinum–etoposide vs platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

The prediction of epidermal growth factor receptor mutation and prognosis of EGFR tyrosine kinase inhibitor by serum ferritin in advanced NSCLC

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial

BRI or BMI: What is More Efficient?

Enhancing Conventional Diabetes Management with Lifestyle and Nutritional Interventions

Gut Health Disorders and its Management

Addressing Sleep Disorders with Integrative Solutions: From Pharmaceuticals to Natural Remedies

MIP: Traumatic Brain Injury : Dr Nikhilesh Jain

Select Specialty

Select Topic